InMed Pharmaceuticals (INM) Interest Expenses (2020 - 2026)

InMed Pharmaceuticals' Interest Expenses history runs 7 years deep, the most recent figure standing at $432768.0 for Q1 2026.

• On a quarterly basis, Interest Expenses fell 51.84% year-over-year to $432768.0 in Q1 2026; TTM through Mar 2026 was $432768.0, a 51.84% decrease from a year earlier, with the FY2025 full-year figure at $806219.0, up 336.88% from the prior year.
• Interest Expenses grew to $432768.0 in Q1 2026 per INM's latest filing, from $19440.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $18.7 million in Q2 2022 and bottomed at -$157701.0 in Q2 2024.
• The 5-year median for Interest Expenses is $574170.0 (2022), against an average of $1.7 million.
• Across the five-year window, Interest Expenses tumbled 100.49% in 2023 and surged 598.5% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $609550.0 in 2022, then jumped by 105.51% to $1.3 million in 2023, then slipped by 19.17% to $1.0 million in 2024, then plunged by 98.08% to $19440.0 in 2025, then soared by 2126.17% to $432768.0 in 2026.
• Per Business Quant, the three latest INM Interest Expenses figures stand at $432768.0 (Q1 2026), $19440.0 (Q4 2025), and $765839.0 (Q3 2025).